FRM
CDLX icon

Fox Run Management’s Cardlytics CDLX Stock Holding History

Fox Run Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,376
Closed -$489K – 801
2024
Q1 		$489K Buy
+3,376
New +$285K 0.11% 378
2021
Q2 		– Sell
-264
Closed -$289K – 354
2021
Q1 		$289K Buy
+264
New +$349K 0.52% 76

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's CDLX Position: Q2 2024 in Review

Fox Run Management sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 3,376 shares — an estimated $489K sold.

Fox Run Management first reported a position in CDLX in Q1 2021 and held it in 2 quarters. The position peaked at $489K in Q1 2024. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

  • Fox Run Management reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
  • Fox Run Management sold 3,376 Cardlytics shares in Q2 2024, an estimated $489K.
  • Fox Run Management first reported a position in Cardlytics in Q1 2021 and held it in 2 quarters.
  • Fox Run Management's Cardlytics position peaked at $489K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Fox Run Management's 13F filing for Q2 2024, filed 13 Aug 2024.